The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL) ...

基于算法的、仅使用G-CSF的动员方案，并根据CD34计数提前使用普乐沙福，实现了100%的采集成功率，促进了早期植入，减少了普乐沙福的使用，并避免了动员失败。这种方法避免了化疗的毒性反应，优化了普乐沙福的使用，防止了移植时间的延迟。 图1。基于CD34 ...

TEL AVIV, Israel, Sept. 11, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare diseases, today announced that the ...

Erratum: ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma Treatment Intensification With Either ...

本综述聚焦粒细胞集落刺激因子（G-CSF），系统梳理其在生殖系统的作用机制与治疗效果，涵盖子宫内膜修复、滋养层发育、免疫抑制、排卵等方面，分析其在薄子宫内膜、反复着床失败等疾病中的应用，为相关研究与临床治疗提供参考。 粒细胞集落刺激因子（G ...

When the use of prophylactic granulocyte-colony stimulating factor (G-CSF) to reduce febrile neutropenia (FN) was decreased in patients receiving chemotherapy for breast cancer, it led to a more than ...

Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...